TSE:4568Pharmaceuticals
Are Daiichi Sankyo Company’s (TSE:4568) ASCO 2026 ADC Data Deepening Its Oncology Moat?
In late May 2026, Daiichi Sankyo announced it would present more than 25 oncology abstracts at the ASCO 2026 meeting, showcasing phase 3 data for Enhertu and Datroway across multiple tumor types alongside earlier-stage DXd antibody-drug conjugate programs.
These data underpin several recent approvals and label expansions for Enhertu and Datroway, underscoring how Daiichi Sankyo is turning its in-house ADC platform and global partnerships into an increasingly broad commercial oncology...